Risk Profile Improvements

  • Securities Litigation (removed) — Securities class action lawsuit alleging false statements about lixivaptan and ZF874 programs was dismissed with prejudice in August 2024 and is no longer active.
NASDAQ: CNTA Centessa Pharmaceuticals plc 10-K

Centessa announces $38/share Lilly acquisition; cleminorexton Phase 2 data supports pivotal trials

Filed March 31, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 24, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade CNTA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 3, 2026 10:44 PM